@laurenthewise1
Generic forms of the drug (levofloxacin) are still approved and sold by other manufacturers.
In December 2017, Janssen Pharmaceuticals discontinued production of both the oral and IV versions of Levaquin. While stopping short of a recall, Janssen withdrew the drug amid mounting concerns and the wide availability of alternative treatment options.

FDA Regulatory Actions on Fluoroquinolones
2008:
The FDA added a black box warning — its most serious type of alert — for fluoroquinolones regarding their increased risk of tendon ruptures and tendinitis.
2013:
The FDA issued a drug safety alert for nerve damage, such as peripheral neuropathy, that can occur at any time after someone starts taking a fluoroquinolone.
2016:
The FDA advised health care providers to avoid prescribing fluoroquinolone drugs for people who suffer from bronchitis, sinusitis and other uncomplicated infections.
2018:
The FDA announced that fluoroquinolone use can increase the risk of heart problems like aortic aneurysms. In addition, the FDA strengthened warnings about mental health risks.